Elsevier,
The Lancet Rheumatology, Volume 5, June 2023
This Article supports SDG 3 by estimating the burden of low back pain, which continues to be the leading cause of disability worldwide. The study predicts that low back pain prevalence will continue to increase, from 619 million people in 2020 to 843 million in 2050. Two-fifths of the burden are due to modifiable risk factors, and a quarter of years lived with disability are attributable to occupational ergonomic factors.
Elsevier,
The Lancet Global Health, Volume 11, June 2023
This Comment supports SDGs 4 and 10 by reviewing the global pledges and resolutions that have been made regarding disabled children (dating back to 1946), and highlighting how the September 2023 global summit on SDGs provides an opportunity to reaffirm global commitments on early childhood development.
Elsevier,
American Journal of Clinical Nutrition, Volume 117, June 2023
This paper concludes that findings suggest that 1) long-term omega-3 fatty acid supplementation may reduce risk of Alzheimer’s disease (AD); 2) dietary omega-3 fatty acid intake, especially DHA, may lower risk of dementia or cognitive decline; and 3) peripheral biomarkers of omega-3 fatty acids may serve as predictors of cognitive decline. However, further investigation is needed to understand the gene–environment interactions involved in the intake of omega-3 fatty acids.
Elsevier,
Pharmacological Research - Modern Chinese Medicine, Volume 7, June 2023
This article explores the potential of Traditional Chinese Medicine (TCM) as a treatment for Alzheimer's disease, highlighting the holistic approach of TCM and its promising results in improving cognitive function in Alzheimer's patients. It emphasizes the need for further rigorous clinical trials to validate these findings.
Elsevier,
eClinicalMedicine, Volume 60, June 2023
This Article supports Sustainable Development Goal 3 by estimating the proportion of dementia attributable to hypertension, finding an overall global population attributable fraction of 15.8%. Results were also broken down by region and age. The authors note that the estimates from this study could help to inform public health policy at global and national levels.
Elsevier,
eBioMedicine, Volume 92, June 2023
This Article supports Sustainable Development Goal 3 by describing a cohort characterization model for Alzheimer’s Disease built on medications and diagnoses data that are widely available in a structured format in electronic health records (EHRs), showing that standard machine learning applied to sequences of EHR data can produce scalable computational characterization of Alzheimer’s disease cohorts.
Elsevier,
eBioMedicine, Volume 92, June 2023
This Article supports Sustainable Development Goal 3 by highlighting differential effects of sleep disturbances on resting-state neural activity in patients on the Alzheimer's disease spectrum relative to healthy adults, suggesting a key role of sleep disturbances in the neurophysiological changes seen in Alzheimer's disease, with implications for basic research and clinical intervention.
Elsevier,
The Lancet Regional Health - Europe, Volume 29, June 2023
This Viewpoint supports Sustainable Development Goal 3 by estimating the potential financial cost of lecanemab, a drug for early Alzheimer's disease, if it were to be approved in Europe at the same price as in the USA. The authors suggest that pricing would be unsustainable and that new payment models will be needed to address affordability and inequalities in access.
